Transactions by persons discharging managerial responsibilities and persons closely associated with them Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 (“Mediclinic”, the “Company” or the “Group”) 30 May 2018 NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM On 24 and 25 May 2018, Mr Danie Meintjes, Chief Executive Officer of Mediclinic International plc, sold a total of 49 423 shares in the Company, being the shares awarded to Mr Meintjes in 2014 under the Mediclinic International Limited Forfeitable Share Plan, which vested on 31 May 2017. Mr Meintjes retained the totality of the shares at the time but has now disposed of them to cover personal tax liabilities. Mr Meintjes continues to hold 123 900 shares in the Company. The notification below is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation. 1. Details of PDMR / person closely associated with them (“PCA”) a) Name Mr Daniël Petrus Meintjes 2. Reason for the notification a) Position / status Chief Executive Officer of the Company b) Initial notification / Initial Notification amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Mediclinic International plc b) LEI 2138002S5BSBIZTD5I60 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares financial instrument Identification Code GB00B8HX8Z88 b) Nature of the Sale of shares awarded in 2014 under the Mediclinic transaction International Limited Forfeitable Share Plan, which vested on 31 May 2017 c) Price(s) and volume(s) Price(s) Volume(s) ZAR 110.01 per share 17 423 d) Aggregated information Aggregated volume 17 423 Price ZAR 110.01 e) Date of the 24 May 2018 transaction f) Place of the Johannesburg Stock Exchange transaction 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary Shares financial instrument Identification Code GB00B8HX8Z88 b) Nature of the Sale of shares awarded in 2014 under the Mediclinic transaction International Limited Forfeitable Share Plan, which vested on 31 May 2017 c) Price(s) and volume(s) Price(s) Volume(s) ZAR 107.01 per share 32 000 d) Aggregated information Aggregated volume 32 000 Price ZAR 107.01 e) Date of the 25 May 2018 transaction f) Place of the Johannesburg Stock Exchange transaction About Mediclinic International plc Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group. Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates. Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia. For further information, please contact: Company Secretary, Link Company Matters Limited Jayne Meacham / Caroline Emmet +44 (0)20 7954 9569 Investor Relations, Mediclinic International plc James Arnold, Head of Investor Relations ir@mediclinic.com +44 (0)20 3786 8181 Media queries FTI Consulting Brett Pollard/Debbie Scott – UK +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000 Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: www.mediclinic.com Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited) NSX sponsor: Simonis Storm Securities (Pty) Ltd Date: 30/05/2018 04:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.